Your browser doesn't support javascript.
A Retrospective, Monocentric Study Comparing Co and Secondary Infections in Critically Ill COVID-19 and Influenza Patients.
Marcoux, Diane; Etienne, Isabelle; Van Muylem, Alain; Bogossian, Elisa Gouvea; Yin, Nicolas; Taccone, Fabio Silvio; Hites, Maya.
  • Marcoux D; Clinic of Infectious Diseases, HUB-Erasme Hospital, 1070 Brussels, Belgium.
  • Etienne I; Department of Pneumology, HUB-Erasme Hospital, 1070 Brussels, Belgium.
  • Van Muylem A; Department of Pneumology, HUB-Erasme Hospital, 1070 Brussels, Belgium.
  • Bogossian EG; Department of Intensive Care, HUB-Erasme Hospital, 1070 Brussels, Belgium.
  • Yin N; Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles, 1070 Brussels, Belgium.
  • Taccone FS; Department of Intensive Care, HUB-Erasme Hospital, 1070 Brussels, Belgium.
  • Hites M; Clinic of Infectious Diseases, HUB-Erasme Hospital, 1070 Brussels, Belgium.
Antibiotics (Basel) ; 11(6)2022 May 24.
Article in English | MEDLINE | ID: covidwho-1911141
ABSTRACT
Few data are available on infectious complications in critically ill patients with different viral infections. We performed a retrospective monocentric study including all of the patients admitted to the intensive care unit (ICU) with confirmed COVID-19 (as of 13 March 2020) or Influenza A and/or B infections (as of 1 January 2015) until 20 April 2020. Coinfection and secondary infections (occurring within and after 48 h from admission, respectively) were recorded. Fifty-seven COVID-19 and 55 Influenza patients were included. Co-infections were documented in 13/57 (23%) COVID-19 patients vs. 40/55 (73%) Influenza patients (p < 0.001), most of them being respiratory (9/13, 69% vs. 35/40, 88%; p = 0.13) and of bacterial origin (12/13, 92% vs. 29/40, 73%; p = 0.25). Invasive aspergillosis infections were observed only in Influenza patients (8/55, 15%). The COVID-19 and Influenza patients presented 1 (0-4) vs. 0 (0-4) secondary infections (p = 0.022), with comparable sites being affected (lungs 35/61, 57% vs. 13/31, 42%; p = 0.16) and causative pathogens occurring (Gram-negative bacteria 51/61, 84% vs. 23/31, 74%; p > 0.99). The COVID-19 patients had longer ICU lengths of stay (15 (-65) vs. 5 (1-89) days; p = 0.001), yet the two groups had comparable mortality rates (20/57, 35% vs. 23/55, 41%; p = 0.46). We report fewer co-infections but more secondary infections in the ICU COVID-19 patients compared to the Influenza patients. Most of the infectious complications were respiratory and of bacterial origin.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Randomized controlled trials Language: English Year: 2022 Document Type: Article Affiliation country: Antibiotics11060704

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Randomized controlled trials Language: English Year: 2022 Document Type: Article Affiliation country: Antibiotics11060704